Inna Martin's departure as Chief Operating Officer of Revium Rx. was reported; the filing names no successor. As of November 6, 2026, Revium Rx. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 20, 2026 to June 22, 2026, naming 2 appointments and 2 departures (Form 8-K, June 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Revium Rx? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Inna Martin · Role: Chief Operating Officer · 8-K, 2026-06-22
- · In / out: Out · Person: Arie Gordashnikov · Role: Chief Financial Officer · 8-K, 2026-06-01
- · In / out: In · Person: Shlomi Schwartzblat · Role: Chairman of the Board · 8-K, 2026-04-20
Revium Rx. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-20 to 2026-06-22. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Revium Rx. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-22 | Out | Chief Operating Officer | 8-K, 2026-06-22 | ||
| 2026-06-01 | Out | Chief Financial Officer | 8-K, 2026-06-01 | ||
| 2026-06-01 | In | Chief Financial Officer | 8-K, 2026-06-01 | ||
| 2026-04-20 | In | Chairman of the Board | 8-K, 2026-04-20 |
Selling to them or working with them? See who runs Revium Rx. now and the warning signs.
Free to see. No signup.
Watch Revium Rx.
Get an email when Revium Rx. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Revium Rx.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Revium Rx.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Revium Rx. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Revium Rx., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Inna Martin, departure reported (filed 2026-06-22). No successor is named in these filings.
- Chief Financial Officer: Arie Gordashnikov, departure reported (filed 2026-06-01). No successor is named in these filings.
- Chairman of the Board: Shlomi Schwartzblat, appointed (filed 2026-04-20).
New leaders reset buying decisions — get the Full Report on Revium Rx.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Revium Rx., with the record behind each one.
Find candidates like Chief Operating Officer at Revium Rx.Every change, in the filing's words
Departing: Inna Martin, Chief Operating Officer
Resignation of Ms. Inna Martin from her positions as Director, Chief Operating Officer and President On June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- ("we", "us", "our", "Revium" or the "Company") and as Chief Operating Officer and President thereof, effective immediately.
- Ms. Martin's resignation was in light of certain differences in expectations between her and the Company.
- At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors.
- In connection with Ms. Martin's departure, the Company's subsidiary, Revium Rx Ltd. ("Revium Ltd.") and Ms. Martin entered into a Termination Agreement and Waiver (the "Separation Agreement"), effective as of June 16, 2026, pursuant to which Ms. Martin's employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026.
- Additionally, the exercise period for Ms. Martin's vested stock options to purchase up to 2,440,000 shares of the Company's common stock has been extended until September 30, 2028.
Departing: Arie Gordashnikov, Chief Financial Officer
Resignation of Mr. Arie Gordashnikov from his position as Chief Financial Officer On May 27, 2026, Mr. Arie Gordashnikov resigned from his position as Chief Financial Officer of Revium Rx.
Appointed: Igor Bluvstein, Chief Financial Officer
Appointment of Mr. Igor Bluvstein as Chief Financial Officer On May 27, 2026, our Board of Directors appointed Mr. Igor Bluvstein to serve as the Chief Financial Officer of the Company and of its subsidiaries, effective immediately.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- ("we," "us," "our," "Revium" or the "company") and of its subsidiaries, effective immediately.
- Mr. Gordashnikov's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Prior to his appointment as Chief Financial Officer, from 2024 through 2025, Mr. Bluvstein served as Chief Financial Officer of Argent BioPharma Ltd. (ASX: RGT; LSE: RGT; OTCQB: RGTLF) and from 2022 through 2024 as Chief Financial Officer of G Medical Innovations Holdings Ltd. (NASDAQ: GMVD).
- Mr. Bluvstein, 44, has over seventeen (17) years of experience in financial leadership across the pharmaceutical, digital health, biotechnology, e-commerce, and petrochemical industries.
- Earlier in his career, from 2020 through 2022 he served as Chief Financial & Operations Officer of MDD Group and from 2016 through 2020 as Regional Chief Financial Officer at Frutarom Industries Ltd. (acquired by International Flavors & Fragrances Inc. (NYSE: IFF)).
- Mr. Bluvstein holds a Bachelor of Arts in Accounting and Economics from the Open University of Israel.
Appointed: Shlomi Schwartzblat, Chairman of the Board
In addition, the Board appointed Mr. Schwartzblat as the Chairman of the Board.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- Appointment of Mr. Amir Avraham as permanent Chief Executive Officer On April 14, 2026, the Board of Directors of Revium Rx ("we," "us," "our," "Revium" or the "company") appointed Mr. Amir Avraham, who has served as the Company's interim Chief Executive Officer, to serve as the permanent Chief Executive Officer of the Company and of its subsidiaries, effective as of February 1, 2026.
- Mr. Avraham was previously appointed as our Chief Executive Officer on an interim basis on May 22, 2025, following Mr. Akunis' resignation from such position.
- Since February 2024, Mr. Avraham has been a financial consultant with the Company, on a part-time basis.
- Prior to his appointment as interim Chief Executive, he served (since 2017) as the General Manager and Chief Financial Officer at OCON Therapeutics, a global biotech and drug device company, operating in Israel and Switzerland.
- In connection with his appointment, our Israeli subsidiary, Revium Ltd., and Mr. Avraham entered into an employment agreement (the "Agreement").
- Pursuant to the Agreement, Mr. Avraham is entitled to a monthly salary of NIS 55,000.
Tools for this story
Each opens in a new tab, filled in for Revium Rx.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.